XTL BIOPHARMACEUTICALS

Company snapshot

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enou

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for XTL BIOPHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for XTL BIOPHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   XTL 6865 — Phase 1

2. May 23, 2026 Clinical update

   Bicifadine — Phase 2

3. May 23, 2026 Clinical update

   Bicifadine — Phase 2

4. May 23, 2026 Clinical update

   XTL-2125 — Phase 1

5. Dec 11, 2012 Patent grant

   Pyrazole compounds

View all clinical trial activity →

• What is XTL BIOPHARMACEUTICALS?

  XTL Biopharmaceuticals is a biotech organization headquartered in Raanana, USA. It trades on NYSE under ticker XTLB. Primary therapeutic focus areas include Chronic Peripheral Neuropathy Pain in Diabetics, Diabetic Peripheral Neuropathy, Chronic Hepatitis C Virus Infection, Hepat

• Is XTL BIOPHARMACEUTICALS publicly traded?

  Yes. XTL BIOPHARMACEUTICALS is listed with ticker XTLB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does XTL BIOPHARMACEUTICALS develop or market?

  We link 1 drug profile(s) where XTL BIOPHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xtl-biopharmaceuticals-ltd#company-drugs.

• What are the latest developments for XTL BIOPHARMACEUTICALS?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does XTL BIOPHARMACEUTICALS focus on?

  XTL BIOPHARMACEUTICALS focuses on Chronic Peripheral Neuropathy Pain in Diabetics, Diabetic Peripheral Neuropathy, Chronic Hepatitis C Virus Infection based on our analysis of their pipeline programs and drug development activities.